INTRODUCTION
Cyclooxygenases (COXs) are the key enzymes in the conversion of arachidonic acid to prostaglandins. There are two COX isoforms-COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and produces prostaglandins for homeostatic functions (1, 2) . COX-2 is highly inducible at inflammation sites and is associated with various human tumors such as colonic carcinoma (3), gastric carcinoma (4), prostate carcinoma (5), malignant melanoma (6), or highgrade gliomas (7) . COX-2 expression in tumor cell lines is also upregulated during increased proliferation (8) , inhibition of apoptosis (9) , and neoangiogenesis (10) . Recent studies indicate that COX-2 is overexpressed in several thyroid carcinomas, particularly papillary carcinoma (11) (12) (13) (14) .
Nitric oxide is produced from L-arginine by nitric oxide synthase (NOS). NOS has one inducible isoform, iNOS, and two constitutively expressed isoforms; endothelial NOS and neuronal NOS (15) . Among all the three NOS isoforms, iNOS synthesizes the largest amount of nitric oxide released by cells in response to cytokines or other agents (16) . The overexpression of iNOS has been demonstrated in chronic inflammatory diseases as well as human tumors, including tumors of the breast, ovary, stomach, head and neck, and central nervous system (17) (18) (19) (20) (21) . It has been reported that iNOS plays an important role in tumorigenesis as a mediator of carcinogenic nitrosamine formation, DNA damage, neovascularization (22) , and apoptosis (23) . A few studies have demonstrated that iNOS is overexpressed in several benign and malignant thyroid lesions (24, 25) .
The aim of the present study was to examine the differences in the immunohistochemical expressions of the COX-2 and iNOS proteins in thyroid neoplasms. Further, we analyzed several clinicopathological findings, patient age, tumor size, thyroid capsular invasion, and lymph node metastasis, in papillary carcinoma cases. The results showed that COX-2 and iNOS were frequently expressed in the PTC and HN specimens, and iNOS was more frequently overexpressed in the FC specimens than in the FA specimens. In PTC, COX-2 and iNOS were significantly overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expression was increased in patients with a large primary tumor (p=0.028). These results suggest that the upregulation of COX-2 and iNOS may contribute to the tumor progression of thyroid gland, particularly in PTC and HN, and iNOS may play an adjuvant role during the tumor progression of FC.
MATERIALS AND METHODS
carcinoma with classical type (PTC) (n=86), follicular adenoma (FA) (n=21), follicular carcinoma (FC) (n=35), medullary carcinoma (MC) (n=3), undifferentiated carcinoma (UC) (n=5), and Hurthle cell neoplasm (HN) (Hurthle cell adenoma, n=2; Hurthle cell carcinoma, n=2). Each specimen was subjected to histological evaluation to confirm the diagnosis, while the relevant clinicopathological information was retrospectively abstracted from patient records. The histopathological slides were reviewed by three pathologists.
Immunohistochemistry
The specimens were formalin-fixed and paraffin-embedded blocks. The tissue blocks were freshly cut into 3 m thick sections onto glass slides. Tissue sections were then deparaffinized in xylene and rehydrated through graded alcohol and deionized water. Afterwards the sections were heated in a microwave oven in 10 mM citrate buffer (pH 6.0) for 15 min at 100℃ for antigen unmasking. Endogenous peroxidase activity of the tissues was inactivated by 10 min incubation in 3% hydrogen peroxide. To block non-specific binding sites, the slides were then treated with 5% goat serum for 15 min at room temperature. The sections were incubated for one hour at room temperature with primary antibody to either COX-2 mouse antihuman monoclonal antibody at a dilution of 1:100 (Mouse anti-COX-2, Clone: COX 229; Zymed laboratories Inc., South San Francisco, CA, U.S.A.) or with iNOS epitope specific rabbit antibody at a dilution of 1:100 (Nitric oxide synthase, inducible: RB-9242-P; Lab vision, Fremont, CA, U.S.A.). After incubation with the primary antibody, the sections were processed using standard avidin-biotin immunohistochemistry, according to the manufacturer's recommendations (Vectastain ABC Elite kit; Vector Laboratories, Burlingame, CA, U.S.A.). Negative controls for the specificity of anti-COX-2 or anti-iNOS antibody were used by omitting the primary antibody, and these were prepared using mouse and rabbit immunoglobulins instead of using each primary antibody individually. Thirty paraffin blocks of normal thyroid tissue were used as negative controls.
The intensity of the staining was scored 0-3 (absent, mild, moderate, strong) ( Fig. 1, 2 ) and the area of positivity was estimated as the percentage of the total area of the tumor (<10%, 10-50%, and >50%). The final score was a combination of these two variables and was calculated as follows: score 0, negative staining or intensity 1+area <10%; score 1, intensity 1+area between 10% and 100% or intensity 2- A B C D 3+area <10%; score 2, intensity 2+area >50% or intensity 3+area between 10% and 50%; score 3, intensity 3+area >50%. A final score of 1-3 was defined as positive immunoreactivity. The scoring was performed independently and in a blinded manner by three pathologists who had no knowledge of the clinical data. Discrepant scoring was determined by consensus.
Statistical analysis
The results were analyzed using one-way ANOVA and chi-square tests. Statistical package for the social sciences (SPSS 12.0) was employed. A p value <0.05 was regarded as statistically significant.
RESULT
Cytoplasmic COX-2 expression (final scores 1-3) was detected in 62 (72.1%) PTC specimens, 5 (23.8%) FA specimens, 10 (28.6%) FC specimens, 0 (0.0%) MC specimen, 1 (20.0%) UC specimen, and 3 (75%) HN specimens. Cytoplasmic iNOS expression (final scores 1-3) was detected in 66 (76.7%) PTC specimens, 4 (19.0%) FA specimens, 13 (37.1%) FC specimens, 0 (0.0%) MC specimen, 3 (60.0%) UC specimens, and 4 (100%) HN specimens. The COX-2 and iNOS proteins were frequently expressed in the PTC and HN specimens. The mean of the COX-2 final scores was 1.37 in the PTC, 0.43 in the FA, 0.49 in the FC, 0.00 in the MC, 0.60 in the UC, and 1.50 in the HN specimens ( Table 1 ). The mean of the iNOS final scores was 1.73 in the PTC, 0.19 in the FA, 0.74 in the FC, 0.00 in the MC, 0.80 in the UC, and 1.75 in the HN specimens. The mean value of the iNOS final scores in the FC specimens was greater than that in the FA specimens (Table 2 ). In the normal thyroid tissue, each final score with regard to COX-2 and iNOS expressions was zero. Significant positive correlations were detected between COX-2 and iNOS expressions (Table 3 ). In PTCs, COX-2 and iNOS expressions increased in the patients over 45 yr of age, and high iNOS expression correlated with the primary tumor size. However, COX-2 and iNOS expressions have not been shown to be associated lymph node metastasis at operation (Table 4 , 5).
DISCUSSION
In this study, the final immunoreactive scores of COX-2 and iNOS expressions were significantly high in the PTC and HN specimens. In contrast, the FA, FC, MC, and UC specimens showed lower COX-2 and iNOS expressions. COX-2 overexpression was closely associated with iNOS expression. The positive correlation between COX-2 and iNOS expressions could be associated with a link between COX-2 and iNOS pathways because nitric oxide (the product of iNOS catalysis) is a regulator of COX-2 activity (26) and diverse prostaglandins (products of COX-2) may affect iNOS expression (26, 27) . It has been observed that COX-2 plays important roles in tumor progression as mediators for the development of tumor vasculature (10), inhibition of apoptosis (9) and increasing tumor cell invasiveness (28, 29) . Although the exact signaling pathways of COX-2-promoted tumorigenesis are yet unknown, several animal studies support a direct role of COX-2 in tumorigenesis since the genetic deletion of COX-2 suppresses tumor growth and multiplicity in mice (30) . Both COX-2 and iNOS overexpressions showed an ageassociated increase in PTCs. Many authors have demonstrated an age-associated increase in COX-2 activity and prostaglandin E2 production in animal models (31) , and Siironen et al. reported that COX-2 expression increased in older patients with PTC (11). They divided the patients into two groups; patients less than 35 yr of age and those older than 55 yr of age. Initially, Ito et al. had reported that COX-2 expression decreased with age in PTCs (32) . They divided patients into those under and over 54 yr of age. But the Union Internationale Contre le Cancer TNM system classifies all PTC patients under 45 yr in a low-risk category, independent of tumor size, extent of tumor, lymph node metastasis, and distant metastasis (33) . In our study, we divided PTC patients into two groups, namely, those under and over 45 yr of age and detected an age-associated increase in COX-2 and iNOS expressions. The results were in agreement with the report of Siironen et al. and demonstrated that the overexpression of COX-2 and iNOS could correlate with the more aggressive behavior of PTC.
Similar to the COX-2 expression, we detected iNOS overexpression in PTC and HN specimens and iNOS expression was increased in patients with a large primary tumor. The iNOS overexpression in the PTC specimens is in line with the previous reports (13, 25) . Previous reports suggested that the nitric oxide released by iNOS might be involved in tumorigenesis as an inhibitor of epithelial cell apoptosis (23) and neoangiogenesis (34) . With regard to the FA and FC specimens, iNOS overexpression was more frequently observed in the FC specimens than in the FA specimens. Among the FC specimens, there were 37.1% positive cases, whereas among the FA specimens, there were only 19.0% positive cases. Although this result is insufficient to arrive at a conclusion, we suggest that iNOS expression analysis could be helpful in understanding the tumor progression of FC.
Overexpression of the COX-2 protein in HN specimen has been reported previously (35) , but the role played by COX-2 and iNOS in HN is unknown. A previous study has shown that COX-2 and iNOS are overexpressed in the swollen cytoplasm of the follicular cells in chronic lymphocytic thyroiditis (13) . The swollen cytoplasm of the follicular cells in chronic lymphocytic thyroiditis and in our HN specimens may have a mitochondrial dysfunction that is related to COX-2 and iNOS.
We have not demonstrated COX-2 and iNOS expression in the three cases of MCs. However, Bell et al. reported COX-2 and iNOS expression in nine cases of MC along with immunohistochemical reactivity for COX-1 and COX-2 enzymes (36). Kim et al. reported that one of two MC cases showed immunohistochemical overexpression for COX-2 (35), and Choe et al. reported that all the five MC cases showed immunohistochemical overexpression for iNOS (24) . The number of MC cases that we have reported here was too small for statistical analysis. The association of COX-2 and iNOS expressions with MC should be further investigated for better understanding of MC tumorigenesis.
In conclusion, the present immunohistochemical study has shown that overexpressions of the COX-2 and iNOS proteins were more frequently observed in PTC and HN specimens than other thyroid neoplasms. Further, FCs tended to show iNOS overexpression more frequently than FAs. The expressions of both COX-2 and iNOS increased in older PTC patients, and iNOS overexpression was correlated with the primary tumor size of PTC. These preliminary data suggest that COX-2 and iNOS expressions could be important molecular events for the tumor progression of PTC and HN, and iNOS expression could play a role in the tumor progression of FC.
